Study: 17% of HCV patients have contraindication to therapy

01/28/2013 | Medscape (free registration)

A study found 17.3% of patients with chronic hepatitis C had a contraindication to pegylated interferon and ribavirin therapy, but most were treatable or transient. Bipolar disorders, anemia and pregnancy were the most common contraindications, according to researchers from State University of New York in Buffalo. Those with contraindications tended to be white, younger, female, unmarried and covered by public insurance.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations